Financial Data and Key Metrics Changes - TG Therapeutics reported approximately $616 million in total global revenue for 2025, with $594 million coming from U.S. net sales of BRIUMVI, marking a 92% year-over-year growth and a 20% sequential growth from Q4 over Q3 [5][20] - The company achieved a net income of $447.2 million for the full year 2025, or $2.77 per diluted share, compared to $23.4 million, or $0.15 per diluted share in 2024 [23][24] Business Line Data and Key Metrics Changes - BRIUMVI U.S. net revenue reached $594 million for the full year, with Q4 net sales of $183 million, reflecting sustained momentum and growth driven by new patient starts and prescriber expansion [12][20] - Breyanzi continues to strengthen its position in the anti-CD20 market, with a balanced mix of treatment-naive and switch patients contributing to its growth [13][14] Market Data and Key Metrics Changes - The company expects U.S. Breyanzi net revenue guidance for 2026 to be between $825 million and $850 million, with total global revenue projected at $875 million to $900 million [16] - The first quarter of 2026 is expected to see U.S. revenue grow sequentially to approximately $185 million to $190 million, despite typical seasonal headwinds [17] Company Strategy and Development Direction - TG Therapeutics aims to maximize the multi-billion dollar BRIUMVI opportunity while expanding its pipeline judiciously for sustained future growth [9] - The company is developing a self-administered subcutaneous BRIUMVI, targeting pivotal top-line data later this year or early next year, with a potential 2028 launch [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for BRIUMVI, citing strong patient persistence and physician confidence as key drivers [30][36] - The company anticipates generating positive cash flow in 2026 and beyond, providing financial flexibility within the biotech sector [9][24] Other Important Information - TG Therapeutics completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in the company's long-term outlook [10][24] - The partnership with Christina Applegate for the Next in MS initiative aims to provide resources and support for individuals living with MS, enhancing the company's presence in the community [11][15] Q&A Session Summary Question: Dynamics of sub-Q uptake in community practices - Management noted that they continue to gain shares in the IV segment, driven by clinical data and operational advantages, with no decrease in switches from Ocrevus to BRIUMVI [27][28] Question: Gross to net assumptions - Management indicated that gross to net can fluctuate, particularly in Q1 due to deductible resets, but this does not represent a structural change in their framework [31] Question: Proportion of new versus switch patients - Management confirmed record new patient enrollments and strong persistence, with repeat patients becoming a larger part of the business [34][36] Question: Incremental investments for sub-Q launch - Management stated that the overlap between the current field force for IV and sub-Q is about 80%, indicating minimal incremental costs for the sub-Q launch [46] Question: Market perspective on ENHANCE trial - Management believes that eliminating the second dose will enhance market share gains, as convenience is highly valued by both patients and centers [70][71]

Financial Data and Key Metrics Changes - Cash, cash equivalents, and marketable securities decreased to $605.1 million as of December 31, 2025, from $861.7 million as of December 31, 2024 [20] - Collaboration revenue increased to $23 million for Q4 2025, compared to $12.9 million for the same quarter in the previous year [21] - R&D expenses decreased to $88.7 million in Q4 2025 from $116.9 million in the prior year quarter [21] - Net loss for Q4 2025 was $95.8 million, down from $128.9 million in the prior-year quarter [22] Business Line Data and Key Metrics Changes - The company achieved rapid enrollment in the HAELO Phase 3 clinical trial with 80 patients, completing enrollment just nine months after dosing the first patient [11] - Enrollment in the MAGNITUDE Phase 3 clinical trial exceeded expectations, with over 650 patients enrolled by October 2025 [8] - The FDA lifted the clinical hold on MAGNITUDE-2, allowing for modifications to the study protocol to enhance patient safety [9] Market Data and Key Metrics Changes - A market research survey indicated that 99% of surveyed patients would be at least somewhat likely to take lonvo-z if approved, with nearly two-thirds stating they would be extremely or very likely to take it [12] - 92% of healthcare providers surveyed indicated they could identify a patient in their practice to whom they would prescribe lonvo-z, representing a significant portion of the treated patient population in the U.S. [13] Company Strategy and Development Direction - The company aims to revolutionize medicine through CRISPR gene editing, focusing on developing one-time treatments with durable efficacy [4][5] - The commercial strategy for lonvo-z includes scaling the field medical team, engaging with treating physicians, and finalizing distribution models [18][34] - The company believes that a one-time treatment like lonvo-z could significantly reduce the financial and emotional burdens on patients compared to current long-term therapies [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming pivotal readout for lonvo-z, which is expected to be the world's first in vivo CRISPR-based gene-editing therapy [18] - The company is confident in completing enrollment for MAGNITUDE-2 in the second half of the year and anticipates a successful launch of lonvo-z next year [20] - Management highlighted the importance of addressing patient safety and regulatory compliance in ongoing trials, particularly in light of recent clinical holds [9][32] Other Important Information - The company has made significant progress in addressing the clinical hold on MAGNITUDE studies, with ongoing engagement with the FDA to ensure patient safety [9][63] - The company is preparing for a BLA submission in the second half of the year, with a focus on ensuring CMC readiness for lonvo-z [45][48] Q&A Session Summary Question: Differences in baseline patient characteristics for HAE study - Management confirmed that the patient populations in the Phase 3 trial are largely overlapping with those in Phase 1/2, designed to represent a standard patient population for HAE [26] Question: Commercial strategy for HAE - Management indicated that the commercial strategy will focus on educating physicians and scaling the field force, with a strong value proposition for patients [34][37] Question: CMC readiness for lonvo-z - Management stated that they are fully prepared for BLA submission and using commercial material in the Phase 3 trial [45][48] Question: FDA's view on clinical hold differences - Management noted that the FDA views the patient populations for PN and CM studies as distinct, influencing their regulatory approach [62] Question: Impact of mitigation strategies on liver enzyme elevations - Management acknowledged that while mitigation strategies are in place, it is unclear if they would have changed the outcome for the patient who experienced severe liver enzyme elevations [72]

Summary of Chemomab Therapeutics FY Conference Call Company Overview - **Company**: Chemomab Therapeutics (NasdaqCM:CMMB) - **Industry**: Biotechnology, focusing on inflammatory and fibrotic diseases - **Lead Asset**: Nebokitug, a first-in-class monoclonal antibody targeting CCL24, involved in inflammation and fibrosis across multiple indications [2][3] Core Points and Arguments Clinical Development - **Primary Indications**: - Primary Sclerosing Cholangitis (PSC): A rare liver fibrotic disease with no FDA-approved drugs, approximately 70,000 patients in major markets [5][6] - Systemic Sclerosis (SSc): An inflammatory disease affecting primarily women, with a market potential exceeding $1.5 billion [20] - **Clinical Trials**: - Completed a successful Phase 2 study for PSC, showing significant anti-inflammatory and anti-fibrotic activity [3][4] - Nebokitug is now positioned as a Phase 3-ready program for PSC, with plans to start the trial with a partner [4][18] - The Phase 2 study included 76 patients, with a focus on moderate to advanced disease [7][10] Efficacy and Safety - **Phase 2 Study Results**: - Met primary and secondary endpoints, showing safety and tolerability [9][12] - Significant improvements in liver stiffness and ELF scores, particularly in patients with moderate to advanced disease [10][11][16] - 93% of eligible patients continued into an open-label extension, indicating high compliance [13] - Clinical events in treated patients were significantly lower (4.8%) compared to historical controls (26%) [17][18] Market Potential - **Revenue Projections**: Potential market for PSC could exceed $1 billion, based on conservative estimates focusing on moderate to advanced disease [6][28] - **Competitive Landscape**: Nebokitug is the only late-stage drug suggesting clear disease modification, unlike others focusing on symptom management [6][18] Future Directions - **Phase 3 Trial Design**: - Will focus on clinical events as primary endpoints, including various complications related to PSC [19] - Discussions with FDA have aligned on trial design for full approval [18] - **Expansion into Other Indications**: - Potential for nebokitug in systemic sclerosis and other fibrotic diseases, leveraging its dual anti-fibrotic and anti-inflammatory mechanism [23][24] Additional Important Information - **Financial Position**: Chemomab reported approximately $20.8 million in cash, sufficient to support activities through the end of 2026, including Phase 3 preparations [39] - **Partnership Strategy**: Seeking partners with financial commitment and expertise in commercialization to enhance trial efficiency and reduce costs [30][33] Conclusion Chemomab Therapeutics is advancing its lead asset, nebokitug, through clinical trials with promising results in treating PSC and potential applications in systemic sclerosis. The company is well-positioned for a Phase 3 trial, with significant market opportunities and a strong focus on disease modification.

Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials [1][3] - The company holds over 270 patents issued and pending, covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer [3] Company Presentation - The CEO, Pete O'Heeron, will present at the BIO Investment & Growth Summit on March 2-3, 2026, in Miami Beach, FL [1] - The company will have a presentation scheduled for 10:15 a.m. ET on March 2 and will be available for one-on-one meetings throughout the event [2] Company Overview - FibroBiologics is based in Houston and represents the next generation of medical advancement in cell therapy and tissue regeneration [3] - The company is actively developing a pipeline of treatments aimed at chronic diseases [3]

NAPLES, FL / ACCESS Newswire / February 26, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, launches Stemtech BioSciences E-Commerce Retail market channel. (Stemtech Corporation - OTCID:STEK) "Live Longer - Live Better - Live Younger" President & COO, John W. ...

Core Insights - PharmAla Biotech Holdings Inc. has entered into an agreement with Spaulding Rehabilitation to provide LaNeo™ MDMA for a clinical trial focused on MDMA-assisted therapy for fibromyalgia [1][2] Company Overview - PharmAla Biotech is a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, including MDMA [8] - The company aims to alleviate the backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, while also developing novel drugs in the same class [8] - PharmAla is currently the only provider of clinical-grade MDMA for patient treatments outside of clinical trials [8] Clinical Trial Details - The clinical trial, titled "Hyperscan Neuroimaging to Reveal the Brain Mechanisms Supporting Analgesia Following MDMA-Assisted Therapy in Fibromyalgia," will be led by Dr. Vitaly Napadow at Spaulding Rehabilitation [2][3] - The study will utilize advanced hyperscan neuroimaging techniques to explore the brain mechanisms involved in pain relief from MDMA-assisted therapy, marking a new application of MDMA beyond PTSD treatment [3][4] Research Collaboration - Under the agreement, PharmAla will provide LaNeo™ MDMA at no cost, in exchange for a license to the study results [2][5] - Spaulding Rehabilitation will deliver comprehensive study results to PharmAla within 90 days of study completion, including group means and regression analysis plots [5] - PharmAla will leverage the findings for potential regulatory submissions, while Spaulding retains the right of first publication in a peer-reviewed journal [5]

Core Insights - The Growth Stock Forum focuses on identifying attractive growth stocks, particularly in the biotech sector, emphasizing risk/reward situations [1] - The biotech Top Picks of the forum achieved a remarkable increase of 137.6% last year, with a compound annual growth rate (CAGR) of 37.2% since 2017 [1] - The core portfolio, LTGP, has also demonstrated a mid-20s CAGR, indicating strong performance in the long-term investment strategy [1]

Core Insights - The article emphasizes the strong performance of biotech stocks, highlighting a 137.6% increase in the Top Picks over the last year and a compound annual growth rate (CAGR) of 37.2% since 2017 [1]. Biotech Sector Performance - The biotech Top Picks have shown significant growth, with a 137.6% increase last year [1]. - The core portfolio, referred to as LTGP, has achieved a mid-20s CAGR, indicating robust long-term performance [1].

Core Insights - Polyrizon Ltd. announced results from a comparative study showing its naloxone formulation has superior nasal deposition compared to a commercial reference product [1][6]. Study Overview - The study was conducted at the University of Parma's Biopharmanet-TEC research center under the supervision of Prof. Fabio Sonvico, focusing on intranasal technologies [2]. - A validated silicone nasal cast model was used for the evaluation, combined with quantitative image analysis [3]. Key Findings - Polyrizon's formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate, compared to 79.6% (±3.0%) for the commercial product [9]. - The formulation showed significantly lower deposition in the lower turbinate region (5.4% vs. 20.4% for the commercial product), which may enhance dosing consistency and systemic delivery efficiency [9]. - The upper/anterior nasal region is critical for rapid systemic drug absorption, and Polyrizon's technology enables controlled regional deposition [5]. Company Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [7]. - The proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal site for drug delivery [7]. - The company is advancing its naloxone program as part of a broader intranasal platform strategy [6].

Core Insights - ImageneBio, Inc. is participating in the 2026 Leerink Global Healthcare Conference from March 8-11, 2026, with a fireside chat scheduled for March 10 at 3:00 PM EST [1] - The company is focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, with its lead program being IMG-007, a nondepleting anti-OX40 monoclonal antibody [1] - Imagene has completed Phase 1b/2a clinical trials for IMG-007 in atopic dermatitis and alopecia areata, and is currently conducting a Phase 2b clinical trial for moderate-to-severe atopic dermatitis [1]